Skip to main navigation Skip to search Skip to main content

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

  • B. B. Koolen
  • , M. J. T. F. D. Vrancken Peeters
  • , J. Wesseling
  • , E. H. Lips
  • , W. V. Vogel
  • , T. S. Aukema
  • , E. van Werkhoven
  • , K. G. A. Gilhuijs
  • , S. Rodenhuis
  • , E. J. T. Rutgers
  • , R. A. Valdés Olmos*
  • *Corresponding author for this work
  • Antoni van Leeuwenhoek Hospital
  • University Medical Center Utrecht

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: The aim of this study was to evaluate the association of primary tumour 18F-fluorodeoxyglucose (FDG) uptake with clinical, histopathological and molecular characteristics of breast cancer patients scheduled for neoadjuvant chemotherapy. Second, we wished to establish for which patients pretreatment positron emission tomography (PET)/CT could safely be omitted because of low FDG uptake. Methods: PET/CT was performed in 214 primary stage II or III breast cancer patients in the prone position with hanging breasts. Tumour FDG uptake was qualitatively evaluated to determine the possibility of response monitoring with PET/CT and was quantitatively assessed using maximum standardized uptake values (SUVmax). FDG uptake was compared with age, TNM stage, histology, hormone and human epidermal growth factor receptor 2 status, grade, Ki-67 and molecular subtype in univariable and multivariable analyses. Results: In 203 tumours (95 %) FDG uptake was considered sufficient for response monitoring. No subgroup of patients with consistently low tumour FDG uptake could be identified. In a univariable analysis, SUV max was significantly higher in patients with distant metastases at staging examination, nonlobular carcinomas, tumours with negative hormone receptors, triple negative tumours, grade 3 tumours, and in tumours with a high proliferation index (Ki-67 expression). After multiple linear regression analysis, triple negative and grade 3 tumours were significantly associated with a higher SUVmax. Conclusion: Primary tumour FDG uptake in breast cancer patients scheduled for neoadjuvant chemotherapy is significantly higher in tumours with prognostically unfavourable characteristics. Based on tumour characteristics associated with low tumour FDG uptake, this study was unable to identify a subgroup of patients unlikely to benefit from pretreatment PET/CT. © Springer-Verlag 2012.
Original languageEnglish
Pages (from-to)1830-1838
JournalEuropean journal of nuclear medicine and molecular imaging
Volume39
Issue number12
DOIs
Publication statusPublished - Dec 2012
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this